206 related articles for article (PubMed ID: 28270453)
21. PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.
Mendes RD; Sarmento LM; Canté-Barrett K; Zuurbier L; Buijs-Gladdines JG; Póvoa V; Smits WK; Abecasis M; Yunes JA; Sonneveld E; Horstmann MA; Pieters R; Barata JT; Meijerink JP
Blood; 2014 Jul; 124(4):567-78. PubMed ID: 24904117
[TBL] [Abstract][Full Text] [Related]
22. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
23. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
24. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
25. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
26. T-ALL can evolve to oncogene independence.
Abdulla H; Vo A; Shields BJ; Davies TJ; Jackson JT; Alserihi R; Viney EM; Wong T; Yan F; Wong NC; Demoen L; Curtis DJ; Alexander WS; Van Vlierberghe P; Dickins RA; McCormack MP
Leukemia; 2021 Aug; 35(8):2205-2219. PubMed ID: 33483615
[TBL] [Abstract][Full Text] [Related]
27. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Li Z; Abraham BJ; Berezovskaya A; Farah N; Liu Y; Leon T; Fielding A; Tan SH; Sanda T; Weintraub AS; Li B; Shen S; Zhang J; Mansour MR; Young RA; Look AT
Leukemia; 2017 Oct; 31(10):2057-2064. PubMed ID: 28260788
[TBL] [Abstract][Full Text] [Related]
28. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
29. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
30. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
Roncero AM; López-Nieva P; Cobos-Fernández MA; Villa-Morales M; González-Sánchez L; López-Lorenzo JL; Llamas P; Ayuso C; Rodríguez-Pinilla SM; Arriba MC; Piris MA; Fernández-Navarro P; Fernández AF; Fraga MF; Santos J; Fernández-Piqueras J
Leukemia; 2016 Jan; 30(1):94-103. PubMed ID: 26216197
[TBL] [Abstract][Full Text] [Related]
31. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
Peng X; Ye Z; Gao Y
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
[TBL] [Abstract][Full Text] [Related]
32. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Hirose K; Inukai T; Kikuchi J; Furukawa Y; Ikawa T; Kawamoto H; Oram SH; Göttgens B; Kiyokawa N; Miyagawa Y; Okita H; Akahane K; Zhang X; Kuroda I; Honna H; Kagami K; Goi K; Kurosawa H; Look AT; Matsui H; Inaba T; Sugita K
Blood; 2010 Aug; 116(6):962-70. PubMed ID: 20519628
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract][Full Text] [Related]
34. [Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].
Nan Z; Liang Y; Fu R; Liu H; Ruan EB; Wang XM; Wang GJ; Qu W; Liu H; Wu YH; Song J; Xing LM; Guan J; Li LJ; Wang HQ; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):556-61. PubMed ID: 23815897
[TBL] [Abstract][Full Text] [Related]
35. Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Venkitachalam S; Chueh FY; Yu CL
Biochem Biophys Res Commun; 2012 Jan; 417(3):1058-62. PubMed ID: 22222369
[TBL] [Abstract][Full Text] [Related]
36. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
37. Genetic and epigenetic determinants mediate proneness of oncogene breakpoint sites for involvement in TCR translocations.
Larmonie NS; van der Spek A; Bogers AJ; van Dongen JJ; Langerak AW
Genes Immun; 2014 Mar; 15(2):72-81. PubMed ID: 24304972
[TBL] [Abstract][Full Text] [Related]
38. SCL/TAL1: a multifaceted regulator from blood development to disease.
Porcher C; Chagraoui H; Kristiansen MS
Blood; 2017 Apr; 129(15):2051-2060. PubMed ID: 28179281
[TBL] [Abstract][Full Text] [Related]
39. LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.
Patel JL; Pournazari P; Haggstrom SJ; Kosari F; Shabani-Rad MT; Natkunam Y; Mansoor A
Histopathology; 2014 Jan; 64(2):226-33. PubMed ID: 24330148
[TBL] [Abstract][Full Text] [Related]
40. Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.
Landry JR; Kinston S; Knezevic K; Donaldson IJ; Green AR; Göttgens B
Blood; 2005 Oct; 106(8):2680-7. PubMed ID: 15994290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
